🔎 Trials Near Me

Gara Jalqabaatti › Kansarii Ovarii › Oregon

Qorannoo klinikaalii Kansarii Ovarii Oregon keessatti

Qorannoo 34 Kansarii Ovarii f Oregon keessatti hirmaatuu jiru.

Magaalota Oregon keessatti

Takkalaa qorannoo (Ingiliffa)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Saint Alphonsus Cancer Care Center-Ontario, Ontario
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 2
Umuriin hundi · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • Oregon Health & Science University (OHSU), Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • Providence Portland Medical Center /ID# 277727, Portland
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 01-Onk-2026 · NCT07024784

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ful-2026 · NCT05877599

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon, Eugene
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 29-Ful-2026 · NCT05128825

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
  • Compass Oncology - West - Tigard /ID# 275101, Tigard
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 29-Ful-2026 · NCT06890338

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05867251

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 22-Ful-2026 · NCT07059845

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • USO - Oncology Associates of Oregon, P. C., Eugene
  • Providence Portland Medical Center, Portland
  • Kaiser Permanente Interstate Medical Office Central, Portland
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07213804

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Providence Cancer Institute, Portland
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 15-Ful-2026 · NCT06915025

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Oncology Associates of Oregon, P.C., Eugene
  • Providence Cancer Institute Franz Clinic, Portland
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 15-Ful-2026 · NCT07214779

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • Asante / Heimann Cancer Center, Medford
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 14-Ful-2026 · NCT06303505

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • Providence Cancer Institute, Portland
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 14-Ful-2026 · NCT06787612

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Providence Portland Medical Center, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06293898

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 03-Ful-2026 · NCT06824467

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • Research Site, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 130 · Saalaa hunda · Haaromfame 21-Hag-2026 · NCT05797168

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Oregon Health and Science University, Portland
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 19-Hag-2026 · NCT07001748

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Providence Cancer Center Oncology and Hematology Care- Eastside, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Hag-2026 · NCT04895709

A Study of MGC026 in Participants With Advanced Solid Tumors

  • Providence Cancer Institute, Portland
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 11-Hag-2026 · NCT06242470

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • Bay Area Hospital, Coos Bay
  • fi 9 dabalataa
Namoota walitti qabaa jira
Umuriin 35 hanga 50 · Dubartoota · Haaromfame 07-Hag-2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Saint Alphonsus Cancer Care Center-Baker City, Baker City
  • Saint Charles Health System, Bend
  • Clackamas Radiation Oncology Center, Clackamas
  • fi 11 dabalataa
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Hag-2026 · NCT06580314

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • USOR Oncology Associates of Oregon, P.C., Eugene
  • Compass Oncology - Rose Quarter, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 04-Hag-2026 · NCT05579366

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Oregon Health & Science University, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 30-Ado-2026 · NCT04657068

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • Oncology Associates of Oregon, P.C., Eugene
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ado-2026 · NCT06161025

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

  • 517, Eugene
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 16-Ado-2026 · NCT06906341

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

  • Providence Cancer Institute Franz Clinic, Portland
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ado-2026 · NCT05768139

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Providence Cancer Institute Franz Clinic, Portland
  • Providence Oncology and Hematology Care Clinic - Westside, Portland
  • Providence St. Vincent Medical Center- Investigational Drug Services, Portland
  • fi 1 dabalataa
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT04389632

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Legacy Medical Group Gynecologic Oncology, Portland
  • Providence Cancer Center Oncology, Portland
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Dubartoota · Haaromfame 02-Ado-2026 · NCT06819007

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

  • USA15-0, Portland
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Cam-2026 · NCT06953089

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Oregon Health Sciences University, Portland
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 fi ol · Saalaa hunda · Haaromfame 20-Ama-2026 · NCT05366881

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  • SCRI - Northwest Cancer Specialists, P.C., Portland
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 fi ol · Dubartoota · Haaromfame 23-Mud-2025 · NCT06690775

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Portland
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin hundi · Saalaa hunda · Haaromfame 28-Onk-2025 · NCT03452774

Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.